- 1057.855
- -1.611-0.15%
Notable Analyst Calls This Week: Disney, Super Micro and Amgen Among Top Picks
12 Out of 17 Healthcare Companies Beat Profit Estimates This Week- Earnings Scorecard
Gilead Exits J&J Royalty Deal for Liver Drug Ahead of Potential FDA Nod
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $72
Adaptimmune Q2 2024 Earnings Preview
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
74 S&P 500 Stocks That Can Beat the Cash Yield - BofA
Gilead Sciences Analyst Ratings
Vericel Analyst Ratings
S&P 500 Tries Its Best to Rebound With Best Day In A Year | Wall Street Today
Gilead Sciences in Charts: Sales From HIV, Liver Disease, and Oncology Therapies Advances in Q2
Gilead Sciences Non-GAAP EPS of $2.01 Beats by $0.41, Revenue of $6.95B Beats by $210M
Pyxis Oncology Draws Buy at Stifel on Lead Asset
J&J, Stryker Among Potential Suitors for Nevro: Wolfe
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
Pfizer Analyst Ratings
10 Health Care Stocks Whale Activity In Today's Session
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
Check Out What Whales Are Doing With PFE